Fulcrum Therapeutics, Inc.

Ownership Transactions Reported by 25 Insiders

	Insiders	Shares	%	Avg Price	Total $
Buys	1	+43.4K	89.4%	$11.35	+$492K
Sells	1	-5.12K	10.6%	$11.53	-$59K
Net	0	+38.2K	78.9%		+$433K

Name	Relationship	Holdings Value	Past Year Net Change	Change %	Report Date
Ra Capital Management, L.P.	10%+ Owner	$79.4M			Sep 12, 2024
Third Rock Ventures III, L.P.	10%+ Owner	$14.3M			Dec 13, 2022
Mark Levin	Director, 10%+ Owner	$13.4M			Nov 10, 2021
Alex Sapir	President & Chief Executive Officer, Director	$1.5M	+$492K	+48.8%	Jul 3, 2024
Christopher Moxham	Chief Scientific Officer	$103K			Aug 10, 2021
Greg Tourangeau	Principal Accounting Officer	$89.8K	-$59.1K	-39.7%	May 7, 2024
Kate Haviland	Director				Jun 17, 2024
Katina Dorton	Director				Jun 17, 2024
Bryan Stuart	President & Chief Executive Officer, Director				Jan 19, 2022
Curtis Gale Oltmans	Chief Legal Officer				Jan 26, 2024
Alan Ezekowitz	Director				Jun 17, 2024
James J. Collins	Director				Jun 17, 2024
Peter Thomson	VP Finance & Accounting				Jan 19, 2022
Sonja Banks	Director				Jun 17, 2024
Melvin Hayes	Chief Operating Officer				Apr 26, 2023
Judith Dunn	President, Research & Development				Jan 19, 2022
Alan A. Musso	Chief Financial Officer				Jan 26, 2024
Esther Rajavelu	Chief Financial Officer				Feb 9, 2023
Rachel King	Director				Nov 12, 2024
Santiago Arroyo	Chief Medical Officer				Nov 7, 2022
Patrick Horn	Chief Medical Officer				Mar 18, 2024
Colin Hill	Director				Jun 17, 2024
James A. Geraghty	Director				Jun 17, 2024
Christopher Morabito	Chief Medical Officer				Jan 19, 2022
Robert J. Gould	Director				Jun 17, 2024

Insider	Symbol	Class	Transaction	%	Value $	* Price $	Shares	Shares Owned	Date	Ownership

* An asterisk sign (*) next to the price indicates that the price is likely invalid.